Evidence review

CJC-1295 and Ipamorelin: A Popular Stack With No Approved Product Behind It

Neither CJC-1295 nor ipamorelin is an approved drug. They are combined because they act on different parts of the growth-hormone axis, which is mechanistically coherent.

The mechanism, which is genuinely coherent

CJC-1295 is a growth-hormone-releasing hormone analogue. Ipamorelin is a ghrelin receptor agonist and growth hormone secretagogue. They act on different receptors in the same axis, and combining them produces a larger GH pulse than either alone.

That is why the stack exists, and the reasoning is sound as far as it goes. The question is what the larger GH pulse produces in a healthy adult over months, and that is not a mechanistic question.

Where this sits on the evidence ladder

We grade every claim in this category against four tiers, because collapsing them is how peptide marketing works.

Tier 1 — approved drug. Premarket review of safety, effectiveness and manufacturing quality. A registry number and a peer-reviewed publication behind each indication.

Tier 2 — human randomised trials, hard endpoints. Not approved for the marketed use, but tested in people against a comparator on something a patient would notice.

Tier 3 — human data without controls. Open-label series, biomarker studies, small uncontrolled cohorts. Useful for generating hypotheses, unreliable for estimating effect.

Tier 4 — animal and mechanistic work. Where most peptide marketing draws its citations. The attrition rate between promising rodent data and demonstrated human benefit is very high across all of pharmacology.

Where this stack sits

Tier 4 shading into Tier 3. There is pharmacological work establishing that these compounds do what they are said to do to hormone levels. There are small human studies of GH response. There is no body of randomised controlled trials in healthy adults measuring body composition, strength, recovery or sleep against a comparator over a meaningful period.

The distance between “raises growth hormone” and “improves recovery and body composition” is exactly the distance this category consistently fails to cover with evidence.

The regulatory position changed on 23 July 2026

This section was materially wrong two days ago and is corrected here, because the direction of travel reversed between the briefing documents and the vote.

What FDA staff said. Agency reviewers recommended against adding all seven peptides under review. For TB-500 they reported being unable to identify a single human clinical study. On BPC-157 the briefing package cited a lack of evidence supporting effectiveness for ulcerative colitis, the indication under review.

What the committee did. Across 23–24 July 2026 the Pharmacy Compounding Advisory Committee recommended six of the seven substances under review — BPC-157, KPV and TB-500 at 8–6 with one abstention, MOTS-c at 7–5 with two, semax at 8–5 and epitalon at 7–5 with one. Only emideltide was rejected, at 6–7. It overrode its own agency's scientists on every substance it recommended. Reporters in the room described an audible reaction when the tally was read.

All eight of the committee's newly added temporary members voted in favour on the first three; six other members voted against and one abstained. The committee has faced scrutiny over members with conflicts of interest.

Two facts that change how to read this

These are indication-specific. Each substance was reviewed against one proposed use, not for blanket compounding. BPC-157 was reviewed for ulcerative colitis — not for tendon or joint recovery, which is what drives nearly all of its consumer demand. TB-500 was reviewed for wound healing. Compounding either for a sports injury would fall outside the reviewed indication even after a listing.

All seven came off Category 2 on 23 April 2026. That reclassification — removal from the list of substances that may not be compounded — is what made this review possible. The July votes were never a re-ban risk; the only question was whether a new lawful channel opens. Coverage framing this as peptides surviving a threat has the direction backwards.

What the vote does not do

Three distinct legal events are being treated as one across most coverage, and the distinction decides what is lawful today.

1. Removal from Category 2 — the list of substances FDA has flagged with significant safety concerns.
2. A PCAC recommendation — what happened on 23 July. Non-binding.
3. Placement on the Category 1 compoundable list — requires formal notice-and-comment rulemaking, which commonly takes 8 to 12 months.

Only the third makes compounding lawful. The FDA is not bound by the recommendation and has gone against this committee before. In 2023 the agency reviewed a batch of popular peptides and declined to add them, stating they may present significant safety risks — which is what pushed these compounds into the grey market they have occupied since.

So nothing changed legally on 23 July. What changed is the probability of a future change, and the market has spent two days reacting as though the two were the same thing.

The safety gap

Sustained manipulation of the growth-hormone axis in healthy adults has not been characterised over years, because the trials that would characterise it have not been run. IGF-1 elevation, glucose tolerance and the theoretical proliferative concerns that attach to GH signalling are all reasons for monitoring rather than assumption.

A programme prescribing this without baseline and interval bloods is not managing those questions.

What to ask

1. Is this compounded by a licensed pharmacy against a prescription, or sold as a research chemical?
2. What human trial supports the outcome being marketed?
3. What is monitored, and what result would stop treatment?
4. What happens to my supply if the FDA declines to add these to the 503A list?

Questions readers actually ask